Why Manufacturing Is the New Competitive Edge in Cell and Gene Therapy

In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Eytan Abraham, the Chief Commercial and Technology Officer at Minaris Advanced Therapies, to dive into how pharma companies can choose the right CDMO partners, the future of cell and gene therapy manufacturing, and the hard-earned lessons behind building sustainable, high-performance organizations in one of the most complex areas of medicine. Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice. The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations. Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.